A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Summary

This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).

Timeline

Start

2006-05-24

Primary completion

2007-03-28

Completion

2007-03-28

Outcome

Met primary endpoint

registry analysis (unspecified test); Rosiglitazone 4 mg Orally Once Daily vs Placebo; p <0.001; Mean Difference (Net) -0.81 (95% CI -1.01 to -0.61); ANCOVA NCT00432679 ↗

Publications

• Background This study has not been published in the scientific literature.

Drugs

Indications